Document Type
Article
Publication Date
5-27-2020
Abstract
Cardiovascular diseases (CVDs) are one of the foremost causes of high morbidity and mortality globally. Preventive, diagnostic, and treatment measures available for CVDs are not very useful, which demands promising alternative methods. Nanoscience and nanotechnology open a new window in the area of CVDs with an opportunity to achieve effective treatment, better prognosis, and less adverse effects on non-target tissues. The application of nanoparticles and nanocarriers in the area of cardiology has gathered much attention due to the properties such as passive and active targeting to the cardiac tissues, improved target specificity, and sensitivity. It has reported that more than 50% of CVDs can be treated effectively through the use of nanotechnology. The main goal of this review is to explore the recent advancements in nanoparticle-based cardiovascular drug carriers. This review also summarizes the difficulties associated with the conventional treatment modalities in comparison to the nanomedicine for CVDs.
Recommended Citation
Pala R, Anju VT, Dyavaiah M, Busi S, Nauli SM. Nanoparticle-mediated drug delivery for the treatment of cardiovascular diseases. Int J Nanomedicine. 2020;15:3741-3769 https://doi.org/10.2147/IJN.S250872
Copyright
The authors
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License
Included in
Cardiology Commons, Cardiovascular Diseases Commons, Nanomedicine Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Other Pharmacy and Pharmaceutical Sciences Commons
Comments
This article was originally published in International Journal of Nanomedicine , volume 15, in 2020. https://doi.org/10.2147/IJN.S250872